A comprehensive registry for eye diseases
Official title: IRIS Registry: Intelligent Research in Sight Registry
Run by American Academy of Ophthalmology · NCT02485847 · Data updated 2026-11-12
This study is creating a national database to help eye doctors track and improve the care they provide to patients with eye diseases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Months and up |
| Sex | All |
| Enrollment | 20000000 (estimated) |
| Sponsor | American Academy of Ophthalmology Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | March 2014 |
| Main results expected | January 2100 |
| Study ends | January 2100 |
| Registry record updated | July 12, 2016 |
| Trial ID | NCT02485847 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry include patients receiving care for various eye diseases who meet specific measure requirements.
✕Probably not a fit
Patients who do not meet the denominator requirements for the registry measures may not benefit from this initiative.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The IRIS Registry is the first nationwide clinical registry focused on eye diseases, developed by the American Academy of Ophthalmology. It serves as a self-improvement tool for ophthalmologists, allowing them to compare patient outcomes and care processes with peers across the country. The registry captures data on patient interactions, interventions, and follow-ups to enhance the quality of eye care. By analyzing this data, practices can identify strengths and weaknesses, manage patient populations effectively, and improve overall practice efficiency.
Why it matters
Potential benefit: If successful, this registry could significantly enhance the quality of eye care delivered to patients.
How similar studies have gone: Other clinical registries have shown success in improving patient outcomes and practice efficiencies, indicating a promising approach for the IRIS Registry.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who meet the denominator requirements for each measure. Exclusion Criteria: * None
Where it's running
-
American Academy of Opthalmology
San Francisco, California, United States Recruiting
Study contacts
- Study coordinator: Andy Khuong
- Email: irisregistry@aao.org
- Phone: 415-561-8500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
Autologous Serum Tears with Hyaluronate vs Standard Serum Tears for Moderate-to-Severe Dry Eye
This study tests whether adding sodium hyaluronate to autologous serum eye drops provides better relief for adults with moderate-to-severe dry eye in one eye, compared with the standard serum drops in the other eye.
-
Two approaches to repeat eyelid surgery for post-operative trichiasis
This project will try whether the newer Bevel-Rotate Advancement Procedure (B-RAP) or the standard Bilamellar Tarsal Rotation (BLTR) gives better results for people in Tanzania who need repeat surgery for post-operative trachomatous trichiasis.
-
How TRYPTYR affects quality of life and the ability to work for people with dry eye
This one-month test will see if TRYPTYR (acoltremon) eye drops help adults with chronic dry eye produce more tears, reduce symptoms, and improve their ability to do work.
-
Course of EYS-associated retinitis pigmentosa in adults from Russia and former CIS
We will follow adults with pathogenic EYS gene variants from Russia and former CIS for four years to try to find reliable vision and retinal measures for future treatments.
-
Dapagliflozin (an SGLT2 inhibitor) for slowing geographic atrophy in dry AMD
This trial will test whether taking dapagliflozin once daily can slow the growth of geographic atrophy in people aged 50 and older with dry age-related macular degeneration.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.